Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense versus concurrent epirubicin-paclitaxel adjuvant chemotherapy in high-risk node-positive breast cancer
ACTRN12609001036202Phase 3Completed
- Sponsor
- HeCOG
- Start
- Jan 2001
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, paclitaxel, cyclophosphamide, methotrexate and fluorouracil in breast cancer, sponsored by HeCOG. Primary endpoints: Time to recurrence and Overall survival. Started Jan 2001; status: completed.
02
Drugs
epirubicinpaclitaxelcyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12609001036202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609001036202.